Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis.

PLoS One · 2025 · PMC11849894 · PMID 39992967

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Nonetheless, it showed a trend towards superior performance compared to dupilumab in the P-score rankings for IGA-0/1 (P-score, 0.8827 and 0.7380) and EASI-75 (P-score, 0.8850 and 0.7613) (Tables S8 and S11 in S1 File).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.